Atherosclerosis remains a major cause of mortality in the US. Even a more striking statistic is subjects with Type 2 diabetes are 4 to 5 times more likely to suffer a heart attack than someone without diabetes. Although much has been learned about the vascular cell components that contribute to atherosclerosis, it has only recently become accepted that immune cells play an important role in atherosclerosis. The mechanisms for how immune cells modulate atherosclerosis are unclear, and this is an emerging field of research that could lead to promising new therapies. We are a long-standing team of investigators who have been studying atherosclerosis and type 2 diabetes for the last 15 years. The focus of this PPG renewal is to study the immunobiology of atherosclerosis. Project 1 will study T regulatory lymphocyte function in atherosclerosis. Project 2 will investigate the synergy between endotoxemia and oxidized cholesteryl esters in TLR-mediated vascular inflammation. Project 3 will test the role of the transcriptional repressor ld3 in modulating B lymphocyte function in atherosclerosis. A Human Phenotyping and Immune Cell Core will provide human blood samples for immune cell phenotyping for each project. The purpose of this Administrative Core (Core A) is to coordinate the PPG by providing scientific administration, grant and fiscal management, and coordination of scientific advisory meetings.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL055798-17
Application #
8510718
Study Section
Special Emphasis Panel (ZHL1-CSR-A)
Project Start
Project End
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
17
Fiscal Year
2013
Total Cost
$127,099
Indirect Cost
$55,292
Name
La Jolla Institute
Department
Type
DUNS #
603880287
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Verbeek, Rutger; Boekholdt, S Matthijs; Stoekenbroek, Robert M et al. (2016) Population and assay thresholds for the predictive value of lipoprotein (a) for coronary artery disease: the EPIC-Norfolk Prospective Population Study. J Lipid Res 57:697-705
Yang, Xiaohong; Lee, Sang-Rok; Choi, Yun-Seok et al. (2016) Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results. J Lipid Res 57:706-13
Harmon, Daniel B; Srikakulapu, Prasad; Kaplan, Jennifer L et al. (2016) Protective Role for B-1b B Cells and IgM in Obesity-Associated Inflammation, Glucose Intolerance, and Insulin Resistance. Arterioscler Thromb Vasc Biol 36:682-91
Choi, Soo-Ho; Kim, Jungsu; Gonen, Ayelet et al. (2016) MD-2 binds cholesterol. Biochem Biophys Res Commun 470:877-80
Park, Kiwon; Mikulski, Zbigniew; Seo, Goo-Young et al. (2016) The transcription factor NR4A3 controls CD103+ dendritic cell migration. J Clin Invest 126:4603-4615
Choi, Soo-Ho; Sviridov, Dmitri; Miller, Yury I (2016) Oxidized cholesteryl esters and inflammation. Biochim Biophys Acta :
Yeang, Calvin; Cotter, Bruno; Tsimikas, Sotirios (2016) Experimental Animal Models Evaluating the Causal Role of Lipoprotein(a) in Atherosclerosis and Aortic Stenosis. Cardiovasc Drugs Ther 30:75-85
Tsimikas, Sotirios (2016) Lipoprotein(a): novel target and emergence of novel therapies to lower cardiovascular disease risk. Curr Opin Endocrinol Diabetes Obes 23:157-64
Leibundgut, Gregor; Lee, Jun-Hee; Strauss, Bradley H et al. (2016) Acute and long-term effect of percutaneous coronary intervention on serially-measured oxidative, inflammatory, and coagulation biomarkers in patients with stable angina. J Thromb Thrombolysis 41:569-80
Cheng, Hsin-Yuan; Gaddis, Dalia E; Wu, Runpei et al. (2016) Loss of ABCG1 influences regulatory T cell differentiation and atherosclerosis. J Clin Invest 126:3236-46

Showing the most recent 10 out of 188 publications